Results 151 to 160 of about 4,129,157 (211)
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial. [PDF]
Sci RepSmadja DM, Massonnaud CR, Philippe A, Rosa M, Luneau S, Rauch A, Peiffer-Smadja N, Gagneux-Brunon A, Poissy J, Gruest M, Ung A, Pourcher V, Raffi F, Piroth L, Bouiller K, Esperou H, Delmas C, Belhadi D, Diallo A, Saillard J, Dechanet A, Mercier N, Dupont A, Lescure FX, Goehringer F, Jaureguiberry S, Danion F, Tolsma V, Cabie A, Courjon J, Leroy S, Mootien J, Mourvillier B, Gallien S, Lanoix JP, Botelho-Nevers E, Wallet F, Richard JC, Reuter J, Gaymard A, Greil R, Martin-Blondel G, Andrejak C, Yazdanpanah Y, Burdet C, Diehl JL, Hites M, Ader F, Susen S, Mentré F, Dupont A, Discovery Study Group. +51 moreeuropepmc +1 more sourceSARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition
, 2023 Limoges M, Irmine Quenum AJ, Chowdhury MMH, Rexhepi F, Namvarpour M, Akbari SA, Rioux-Perreault C, Nandi M, Lucier J, Lemaire-Paquette S, Premkumar L, Durocher Y, Cantin A, Lévesque S, Dionne IJ, Menendez A, Ilangumaran S, Allard-Chamard H, Piché A, Ramanathan S. +19 moreeuropepmc +1 more sourceGlycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. [PDF]
Diabetes Care, 2020 Brown SA, Beck RW, Raghinaru D, Buckingham BA, Laffel LM, Wadwa RP, Kudva YC, Levy CJ, Pinsker JE, Dassau E, Doyle FJ, Ambler-Osborn L, Anderson SM, Church MM, Ekhlaspour L, Forlenza GP, Levister C, Simha V, Breton MD, Kollman C, Lum JW, Kovatchev BP, iDCL Trial Research Group. +22 moreeuropepmc +1 more sourceImpact of a tailored exercise regimen on physical capacity and plasma proteome profile in post-COVID-19 condition. [PDF]
Front PhysiolChowdhury MMH, Fontaine MN, Lord SE, Quenum AJI, Limoges MA, Rioux-Perreault C, Lucier JF, Cliche DO, Levesque D, Boisvert FM, Cantin AM, Allard-Chamard H, Menendez A, Ilangumaran S, Piché A, Dionne IJ, Ramanathan S. +16 moreeuropepmc +1 more source
